{"organizations": [], "uuid": "d438b593ac9842519c1f656b4a8995bd47b96dde", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180412.html", "section_title": "Archive News &amp; Video for Thursday, 12 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-invokana-demonstrates-renal-protec/brief-invokana-demonstrates-renal-protective-benefits-in-patients-with-type-2-diabetes-mellitus-and-chronic-kidney-disease-idUSFWN1RP0N1", "country": "US", "domain_rank": 408, "title": "BRIEF-Invokana Demonstrates Renal Protective Benefits In Patients With Type 2 Diabetes Mellitus And Chronic Kidney Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.992, "site_type": "news", "published": "2018-04-12T20:25:00.000+03:00", "replies_count": 0, "uuid": "d438b593ac9842519c1f656b4a8995bd47b96dde"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-invokana-demonstrates-renal-protec/brief-invokana-demonstrates-renal-protective-benefits-in-patients-with-type-2-diabetes-mellitus-and-chronic-kidney-disease-idUSFWN1RP0N1", "ord_in_thread": 0, "title": "BRIEF-Invokana Demonstrates Renal Protective Benefits In Patients With Type 2 Diabetes Mellitus And Chronic Kidney Disease", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "johnson & johnson", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - Johnson & Johnson:\n* INVOKANAÂ® (CANAGLIFLOZIN) DEMONSTRATED SIGNIFICANT RENAL PROTECTIVE BENEFITS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE\n* ANALYSIS SHOWING INVOKANA IMPROVED RENAL OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES MELLITUS WITH/AT HIGH RISK FOR CV DISEASE Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-12T20:25:00.000+03:00", "crawled": "2018-04-13T18:03:26.054+03:00", "highlightTitle": ""}